학술논문
Is Intragastric Botulinum Toxin A Injection Effective in Obesity Treatment?
Document Type
Clinical report
Source
Surgery Research and Practice. October 1, 2020, Vol. 2020
Subject
Language
English
ISSN
2356-7759
Abstract
Author(s): Bulent Kaya (corresponding author) [1]; Nuriye Esen Bulut [2]; Mahir Fersahoglu [2] 1. Introduction Obesity has become an epidemic disease in the past years. Genetic, social, psychological, and behavioural [...]
Aims. The objective of this prospective study was to evaluate the efficacy of intragastric botulinum toxin A (BTX-A) injection for the treatment of obesity. Materials and Methods. The study was performed between January and August 2019. This is a prospective study. After 6-12 hours of fasting, the patients were submitted to upper GI endoscopy under sedation for the injection of BTX-A. A total of 250U of BTA-X was diluted with 10ml of 0.9% saline. Injections were administered into the gastric antrum, each containing 1ml of prepared solution (25U BX-A+1ml saline). Continuous data were compared using a two-sample t-test. Statistical significance was determined as P≤0.05. All statistical analysis was performed using SPSS for Windows 22.1 software (SPSS, Chicago, IL, USA). Results. A total of 56 patients were studied. Mean weight before gastric Botox was 85.25±14.02, and mean weight after gastric Botox was 76.98±12.68. Mean weight loss was approximately 9kg in studied patients. BMI decreased about 3 units. The mean time for maximum weight loss was 60.39±37.43 days. A total of 49 patients (87.5%) had reported decrease in appetite and early satiety. About 53.6% of patients were satisfied. No complications resulting from the endoscopic procedure were observed in this series. Conclusions. Intragastric BTX-A injection can be beneficial in weight loss. It is a minimally invasive, cost-effective procedure, without serious side effects.
Aims. The objective of this prospective study was to evaluate the efficacy of intragastric botulinum toxin A (BTX-A) injection for the treatment of obesity. Materials and Methods. The study was performed between January and August 2019. This is a prospective study. After 6-12 hours of fasting, the patients were submitted to upper GI endoscopy under sedation for the injection of BTX-A. A total of 250U of BTA-X was diluted with 10ml of 0.9% saline. Injections were administered into the gastric antrum, each containing 1ml of prepared solution (25U BX-A+1ml saline). Continuous data were compared using a two-sample t-test. Statistical significance was determined as P≤0.05. All statistical analysis was performed using SPSS for Windows 22.1 software (SPSS, Chicago, IL, USA). Results. A total of 56 patients were studied. Mean weight before gastric Botox was 85.25±14.02, and mean weight after gastric Botox was 76.98±12.68. Mean weight loss was approximately 9kg in studied patients. BMI decreased about 3 units. The mean time for maximum weight loss was 60.39±37.43 days. A total of 49 patients (87.5%) had reported decrease in appetite and early satiety. About 53.6% of patients were satisfied. No complications resulting from the endoscopic procedure were observed in this series. Conclusions. Intragastric BTX-A injection can be beneficial in weight loss. It is a minimally invasive, cost-effective procedure, without serious side effects.